United States· US:58411-483_47abdfc2-e98e-b14e-e063-6294a90a9fae
CLE DE PEAU BEAUTE CORRECTING VEIL n
A medicinal product containing ensulizole; octinoxate; titanium dioxide, registered in United States by SHISEIDO AMERICAS CORPORATION.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ENSULIZOLE; OCTINOXATE; TITANIUM DIOXIDE
- Manufacturer
- SHISEIDO AMERICAS CORPORATION
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1158411483101 BOTTLE in 1 CARTON (58411-483-10) / 37 mL in 1 BOTTLE
- ndc1158411-483-10
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3e9fd7eb-75b8-443e-b925-d86e0d28cb6b GET /v1/drugs/3e9fd7eb-75b8-443e-b925-d86e0d28cb6b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "TOPICAL",
"source": "ndc",
"strength": ".386; 1.119; .9264",
"substance": "ENSULIZOLE; OCTINOXATE; TITANIUM DIOXIDE",
"productndc": "58411-483",
"dosage_form": "CREAM",
"dea_schedule": null,
"strength_unit": "g/37mL; g/37mL; g/37mL",
"application_number": "M020",
"marketing_category": "OTC MONOGRAPH DRUG"
}See everything about ensulizole; octinoxate; titanium dioxide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.